We’re working to ensure GPs and community teams have all the necessary skills to provide seamless care following earlier diagnoses.

VCP disease

VCP disease refers to conditions caused by a mutation of the Valosin Containing Protein (VCP) gene. It is inherited in an autosomal dominant manner and primarily presents as an adult-onset condition affecting muscle, bone and brain.

Another term for VCP disease is Inclusion Body Myopathy associated with Paget’s Disease of Bone and Frontotemporal Dementia (IBMPFD). A person with IBMPFD may have one, two or all of the following:

Inclusion Body Myopathy (IBM)
Paget’s Disease of Bone (PDB)
Frontotemporal Dementia (FTD)

While there is an approved treatment for Paget’s Disease of Bone, unfortunately there are no known treatments for Inclusion Body Myopathy or Frontotemporal Dementia.

For more information on VCP disease, please visit Cure VCP Disease’s website.

AMO Pharma announces AMO-02 clinical trial

AMO-Pharma announces the initiation of REACH-CDM clinical trial
Important announcement for adults with DMD

MDUK announces completion of two projects we funded into DMD.
Update on stoppage of SIDEROS clinical trial

Update on stoppage of SIDEROS clinical trial for Raxone/idebenone
PepGen secures $45million investment

PepGen’s work in molecular patches seeks to help people with DMD.